Julie VanOrsdel Daves - Jun 1, 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
SVP Clinical Development Oper.
Signature
/s/ Amy E. Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jun 1, 2023
Transactions value $
$0
Form type
4
Date filed
6/2/2023, 05:16 PM
Previous filing
Sep 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 0 Jun 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +54K $0.00 54K Jun 1, 2023 Common Shares 54K $2.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024.